Silence Therapeutics closes upsized $201.3 million ADS follow-on offering at $13.5 each
SLN•Upsized follow-on offering closes
Silence Therapeutics closed an upsized underwritten public offering of 14,907,407 ADSs at $13.50 per ADS.
Gross proceeds totaled about $201.3 million before underwriting discounts, commissions, and offering expenses.
Full exercise of underwriters’ option included
The deal size included the full exercise of the underwriters’ option for an additional 1,944,444 ADSs.
Each ADS represents three ordinary shares of £0.05 each.
